Case report of suspected rhabdomyolysis during treatment with trabectedin in a patient with metastatic leiomyosarcoma

Case Reports in Oncology

Volumn 3, Issue 3, 2010, Pages 477-479

  Lamm, W ^a   Amann, G ^a   Brodowicz, T ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Leiomyosarcoma; Rhabdomyolysis; Trabectedin

Indexed keywords

CREATININE; DEXAMETHASONE; DOXORUBICIN; IFOSFAMIDE; SEROTONIN 3 ANTAGONIST; SORAFENIB; TRABECTEDIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG DOSE REDUCTION; HUMAN; LEIOMYOSARCOMA; MALE; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 78751549537     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000323261     Document Type: Article

References (9)

1. Maki RG, D'Adamo DR, Keohan ML, Saulle M, Schuetze SM, Undevia SD, Livingston MB, Cooney MM, Hensley ML, Mita MM, Takimoto CH, Kraft AS, Elias AD, Brockstein B, Blachè NE, Edgar MA, Schwartz LH, Qin LX, Antonescu CR, Schwartz GK: Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol 2009;27:3133-3140.
2. Fletcher CDM, Unni KK, Mertens F (eds): Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon, France: IARC Press; 2002
3. Cartner NJ, Keam SJ: Trabectedin: A review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007;67:2257-2276.
4. Soares DG, Escargueil AE, Poindessous V, Sarasin A, de Gramont A, Bonatto D, Henriques JA, Larsen AK: Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci USA 2007;104:13062-13067.
5. Garcia-Carbonero R, Supko JG, Manola J, Seiden MV, Harmon D, Ryan DP, Quigley MT, Merriam P, Canniff J, Goss G, Matulonis U, Maki RG, Lopez T, Puchalski TA, Sancho MA, Gomez J, Guzman C, Jimeno J, Demetri GD: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-1490.
6. Le Cesne A, Blay JY, Judson I, Van Oosterom A, Verweij J, Radford J, Lorigan P, Rodenhuis S, Ray-Coquard I, Bonvalot S, Collin F, Jimeno J, Di Paola E, Van Glabbeke M, Nielsen OS: Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-584. Erratum in: J Clin Oncol 2005;23:5276.
7. Yovine A, Riofrio M, Blay JY, Brain E, Alexandre J, Kahatt C, Taamma A, Jimeno J, Martin C, Salhi Y, Cvitkovic E, Misset JL: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-899.
8. Demetri G, Chawla S, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Góez J, Park YC, Le Cesne A: Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009;27:4188-4196.
9. Taamma A, Misset JL, Riofrio M, Guzman C, Brain E, Lopez Lazaro L, Rosing H, Jimeno JM, Cvitkovic E: Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol 2001;19:1256-1265.